What changed in the LMRI analyst rating on February 9, 2026?

Raymond James upgraded the LMRI analyst rating from Outperform to Strong Buy on February 9, 2026. The headline move was reported by TheFly and showed a small immediate price change of 0.13% ($0.02).

Does the Raymond James note include a new LMRI price target?

The public summary reported by TheFly did not list a new LMRI price target in the headline. Investors should consult the full Raymond James research note for explicit price guidance before making decisions.

How should investors interpret the LMRI analyst rating upgrade?

A Strong Buy from Raymond James signals higher conviction in upside potential for Lumexa Imaging Holdings, Inc. Common Stock. Use the upgrade as one input alongside financials, results, and sector trends before changing positions.

What is Meyka AI’s current view after the LMRI analyst rating change?

Meyka AI rates LMRI with a grade of B. That grade reflects benchmark comparison, sector performance, growth metrics, and analyst consensus. We will update the grade if follow-up coverage or results change the outlook.

Analyst Ratings

LMRI Lumexa Imaging Holdings, Inc. Common Stock Strong Buy Raymond James Feb 2026

ByDanny Kontos February 10, 2026February 10, 2026

Raymond James upgraded the LMRI analyst rating to Strong Buy on February 9, 2026. The firm moved Lumexa Imaging Holdings, Inc. Common Stock from Outperform to Strong Buy, a notable step given limited recent analyst activity on LMRI. The upgrade was reported by TheFly and coincided with a small intraday move of 0.13% ($0.02). Investors should treat this change as a catalyst signal rather than a guarantee, and weigh company fundamentals and market context alongside the new recommendation.